Trilok Parekh - Publications, H-index & Citations

Trilok Parekh

Johnson & Johnson

25H指数

124论文数

3.4K被引数

收录论文 23

发表时间

Relative Effectiveness of Talquetamab Versus Real-World Physician’s Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment Comparison 塔克奎他单抗相较于真实世界中医生选择治疗方案在复发/难治性多发性骨髓瘤患者中的相对有效性：基于间接治疗比较的更新结果

Clinical Lymphoma Myeloma and Leukemia

IF2.7

2025-12-19

PREAI

Jing Christine Ye; Noa Biran; Sandhya Nair; Xiwu Lin; Keqin Qi; Eric M. Ammann; Thomas Renaud; Bonnie W. Lau; Jenny Zhang; Trilok Parekh; Kathleen S. Gray; Xinke Zhang; Luciano J. Costa

Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis 复发/难治性多发性骨髓瘤伴髓外病灶患者的结局：一项Meta分析

Annals of Hematology

IF2.4

2025-12-03

OAAI

Peter M. Voorhees; Shaji Kumar; Saad Z. Usmani; Jing Christine Ye; Yael C. Cohen; Emma Scott; Robin L. Carson; Christoph Heuck; Ryan Gan; Benjamin Ackerman; Jenny Zhang; Eleanor Caplan; Trilok Parekh; María-Victoria Mateos

Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent 三药类暴露的复发/难治性多发性骨髓瘤中塔奎他单抗与真实世界医生选择治疗的比较疗效：MonumenTAL-1与LocoMMotion/MoMMent的更新分析

Advances in Therapy

IF4

2025-11-28

OAAI

Hermann Einsele; Philippe Moreau; Nizar Bahlis; Manisha Bhutani; Laure Vincent; Lionel Karlin; Aurore Perrot; Hartmut Goldschmidt; Niels W. C. J. van de Donk; Enrique M. Ocio; Joaquín Martínez López; Paula Rodríguez-Otero; Dominik Dytfeld; Andrzej Jakubowiak; Carolina Schinke; Britta Besemer; Sébastien Anguille; Salomon Manier; Leo Rasche; Raphael Teipel; Christof Scheid; Charlotte Pawlyn; Michele Cavo; Joris Diels; Francesca Ghilotti; Bonnie W. Lau; Thomas Renaud; Oleksiy Orel; Fenny Ong; Diogo F. Ramos; Eric Ammann; Trilok Parekh; Claire Albrecht; Katja Weisel; María-Victoria Mateos

Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma 新诊断多发性骨髓瘤移植适合患者中，皮下注射达雷木单抗联合硼替佐米、沙利度胺和地塞米松用药的真实世界数据

ANNALS OF HEMATOLOGY

IF2.4

2025-04-30

OAAI

Hungria, Vania; Moura, Fernanda Lemos; Costa, Abel; Ribeiro, Eduardo Flavio Oliveira; Soares, Paulo; Lima, Juliana Souza; Ricci, Lisa Aquaroni; Arrais-Rodrigues, Celso; Nucci, Fabio Moore; de Moraes Lima, Marinus; de Magalhaes Filho, Roberto Jose Pessoa; Bhaumik, Amitabha; Parekh, Trilok; Borgsten, Fredrik; Carson, Robin; Trufelli, Damila C.; de Queiroz Crusoe, Edvan

Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Talquetamab 与真实世界医生选择治疗方案：在经三药类治疗过的复发/难治性多发性骨髓瘤患者中的比较疗效

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

IF2.7

2025-02-01

PREAI

Ye, Jing Christine; Biran, Noa; Nair, Sandhya; Lin, Xiwu; Qi, Keqin; Londhe, Anil; Ammann, Eric; Renaud, Thomas; Kane, Colleen; Parekh, Trilok; Gray, Kathleen; Peterson, Steve; Costa, Luciano J.

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma 在三重暴露的复发/难治性多发性骨髓瘤患者的运动和运动研究中，Talquetamab与当前治疗方法的比较疗效

ADVANCES IN THERAPY

IF4

2024-02-24

OAAI

Einsele, Hermann; Moreau, Philippe; Bahlis, Nizar; Bhutani, Manisha; Vincent, Laure; Karlin, Lionel; Perrot, Aurore; Goldschmidt, Hartmut; van de Donk, Niels W. C. J.; Ocio, Enrique M.; Martinez-Lopez, Joaquin; Rodriguez-Otero, Paula; Dytfeld, Dominik; Diels, Joris; Strulev, Vadim; Haddad, Imene; Renaud, Thomas; Ammann, Eric; Cabrieto, Jedelyn; Perualila, Nolen; Gan, Ryan; Zhang, Youyi; Parekh, Trilok; Albrecht, Claire; Weisel, Katja; Mateos, Maria-Victoria

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

CLINICAL CANCER RESEARCH

IF10.2

2019-08-15

199

OAAI

Bahleda, Rastislav; Italiano, Antoine; Hierro, Cinta; Mita, Alain; Cervantes, Andres; Chan, Nancy; Awad, Mark; Calvo, Emiliano; Moreno, Victor; Govindan, Ramaswamy; Spira, Alexander; Gonzalez, Martha; Zhong, Bob; Santiago-Walker, Ademi; Poggesi, Italo; Parekh, Trilok; Xie, Hong; Infante, Jeffrey; Tabernero, Josep

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

CANCER

IF5.1

2019-06-07

OAAI

Patel, Shreyaskumar; von Mehren, Margaret; Reed, Damon R.; Kaiser, Pamela; Charlson, John; Ryan, Christopher W.; Rushing, Daniel; Livingston, Michael; Singh, Arun; Seth, Rahul; Forscher, Charles; D'Amato, Gina; Chawla, Sant P.; McCarthy, Sharon; Wang, George; Parekh, Trilok; Knoblauch, Roland; Hensley, Martee L.; Maki, Robert G.; Demetri, George D.

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients wits advanced liposarcoma or leiomyosarcoma trabectedin在老年肉瘤患者中的疗效和耐受性: 来自trabectedin或达卡巴嗪在晚期脂肪肉瘤或平滑肌肉瘤患者中的III期随机对照研究的亚组分析

ANNALS OF ONCOLOGY

IF65.4

2018-09-01

OAAI

Jones, R. L.; Demetri, G. D.; Schuetze, S. M.; Milhem, M.; Elias, A.; Van Tine, B. A.; Hamm, J.; McCarthy, S.; Wang, G.; Parekh, T.; Knoblauch, R.; Hensley, M. L.; Maki, R. G.; Patel, S.; von Mehren, M.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

INVESTIGATIONAL NEW DRUGS

IF2.7

2017-11-27

PREAI

Calvo, Emiliano; Azaro, Analia; Rodon, Jordi; Dirix, Luc; Huizing, Manon; Senecal, Francis Mark; LoRusso, Patricia; Yee, Lorrin; Poggesi, Italo; de Jong, Jan; Triantos, Spyros; Park, Youn C.; Knoblauch, Roland E.; Parekh, Trilok V.; Demetri, George D.; von Mehren, Margaret

Pharmacokinetics (PK) of the pan-FGFR inhibitor erdafitinib in urothelial carcinoma

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Tabernero, J.; Infante, J. R.; Mita, A.; Keung, C.; Skee, D.; Xie, H.; Parekh, T.; De Porre, P.; Luo, F. R.; Soria, J-C.

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma 比较硼替佐米联合聚乙二醇化脂质体多柔比星与硼替佐米单独治疗复发或难治性多发性骨髓瘤患者的随机试验的最终总生存期结果

CANCER

IF5.1

2016-05-18

OAAI

Orlowski, Robert Z.; Nagler, Arnon; Sonneveld, Pieter; Blade, Joan; Hajek, Roman; Spencer, Andrew; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J.; Suvorov, Alexander N.; Xiu, Liang; Cakana, Andrew; Parekh, Trilok; San-Miguel, Jesus F.

Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Patel, S.; Von Mehren, M.; Reed, D.; Agulnik, M.; Kaiser, P.; Charlson, J.; Kraft, A.; Hamm, J.; Karnad, A.; Ryan, C.; Rushing, D.; Meyer, C.; Khokhar, N. Z.; McCarthy, S.; Park, Y. C.; Knoblauch, R. E.; Parekh, T. V.; Maki, R. G.; Demetri, G. D.

Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Demetri, G.; Patel, S. R.; Thomas, S.; Livingston, M.; Undevia, S. D.; Richardson, G.; Singh, A. S.; Seth, R.; Forscher, C.; Hinshaw, I.; Hussein, A.; D'Amato, G.; Chawla, S.; Khokhar, N. Z.; Park, Y. C.; Knoblauch, R. E.; Parekh, T. V.; Maki, R. G.; Von Mehren, M.

Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Von Mehren, M.; Demetri, G. D.; Schuetze, S. M.; Jones, R. L.; Milhem, M.; Elias, A.; Van Tine, B. A.; Hamm, J.; Khokhar, N. Z.; McCarthy, S.; Park, Y. C.; Knoblauch, R. E.; Parekh, T. V.; Maki, R. G.; Patel, S. R.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study BRCA1和XPG突变对晚期卵巢癌患者对小梁蛋白酶和聚乙二醇化脂质体阿霉素治疗反应的影响: OVA-301 3期研究的探索性分析

ANNALS OF ONCOLOGY

IF65.4

2015-05-01

OAAI

Monk, B. J.; Ghatage, P.; Parekh, T.; Henitz, E.; Knoblauch, R.; Matos-Pita, A. S.; Nieto, A.; Park, Y. C.; Cheng, P. S.; Li, W.; Favis, R.; Ricci, D.; Poveda, A.

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis 小梁蛋白联合聚乙二醇脂质体阿霉素 (PLD) 与PLD在复发性卵巢癌中的比较: 总体生存分析

EUROPEAN JOURNAL OF CANCER

IF7.1

2012-10-01

PREAI

Monk, Bradley J.; Herzog, Thomas J.; Kaye, Stanley B.; Krasner, Carolyn N.; Vermorken, Jan B.; Muggia, Franco M.; Pujade-Lauraine, Eric; Park, Youn C.; Parekh, Trilok V.; Poveda, Andres M.

Prediction of Overall Survival (OS) Adjusted by Continuous Platinum-free Interval (PFI) at Fixed Timepoints in Patients With Recurrent Ovarian Cancer (ROC) - Results From OVA-301

EUROPEAN JOURNAL OF CANCER

IF7.1

2011-09-01

PREAI

Poveda Velasco, A.; Monk, B.; Kaye, S.; Vermorken, J.; Nieto, A.; Gomez, J.; Park, Y.; Parekh, T.; Colombo, N.; Vergote, I.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Trabectedin联合聚乙二醇化多柔比星脂质体治疗复发性卵巢癌可延迟三线化疗并延长无铂间隔时间

ANNALS OF ONCOLOGY

IF65.4

2011-01-01

OAAI

Kaye, S. B.; Colombo, N.; Monk, B. J.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-Cisarz, E.; Hagberg, H.; Vergote, I.; Lebedinsky, C.; Parekh, T.; Santabarbara, P.; Park, Y. C.; Nieto, A.; Poveda, A.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Trabectedin联合聚乙二醇化多柔比星脂质体治疗复发性卵巢癌: OVA 301 III期随机试验的部分铂敏感 (无铂间隔6-12个月) 亚群的结果

ANNALS OF ONCOLOGY

IF65.4

2011-01-01

127

OAAI

Poveda, A.; Vergote, I.; Tjulandin, S.; Kong, B.; Roy, M.; Chan, S.; Filipczyk-Cisarz, E.; Hagberg, H.; Kaye, S. B.; Colombo, N.; Lebedinsky, C.; Parekh, T.; Gomez, J.; Park, Y. C.; Alfaro, V.; Monk, B. J.

研究方向